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ABSTRACT
Objective To propose a clinical score for the optimal
antenatal diagnosis of fetal lower urinary tract obstruction
(LUTO) in the second and third trimesters of pregnancy,
as an alternative to the commonly used ultrasound triad
of megacystis, keyhole sign and hydronephrosis.
Methods This was a national retrospective study carried
out at the eight tertiary fetal medicine units (FMUs)
in The Netherlands. Only cases referred for megacystis
from the second trimester onwards and with a clear
postnatal diagnosis were included in the study. At referral,
data were collected on amniotic fluid volume, renal
cortical appearance, bladder volume, hydronephrosis,
fetal ascites, ureteral size, keyhole sign, fetal sex and
gestational age. Multivariate analysis was performed,
starting by including all antenatal variables, and then
excluding the weakest predictors using the backward
stepwise strategy.
Results Over a 7-year period, 312 fetuses with a
diagnosis of megacystis were referred to the eight Dutch
tertiary FMUs. A final diagnosis was achieved in 143
cases, including 124 of LUTO and 19 reclassified
after birth as non-obstructive megacystis. The optimal
bladder volume cut-off for prediction of LUTO was
35 cm3 (area under the curve (AUC)= 0.7, P =0.03).
The clinical score formulated on the basis of the
multivariate analysis included fetal sex, degree of bladder
distension, ureteral size, oligo- or anhydramnios and
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gestational age at referral. The combination of these five
variables demonstrated good accuracy in discriminating
LUTO from non-obstructive megacystis (AUC= 0.84,
P < 0.001), compared with the poor performance of the
ultrasound triad (AUC= 0.63, P = 0.07).
Conclusions We propose a clinical score that combines
five antenatal variables for the prospective diagnosis of
congenital LUTO. This score showed good discriminative
capacity in predicting LUTO, and better diagnostic
accuracy compared with that of the classic ultrasound
triad. Future studies to validate these results should be
carried out in order to refine antenatal management of
LUTO and prevent inappropriate fetal interventions.
© 2017 The Authors. Ultrasound in Obstetrics &
Gynecology published by John Wiley & Sons Ltd on
behalf of the International Society of Ultrasound in
Obstetrics and Gynecology.
INTRODUCTION
The term lower urinary tract obstruction (LUTO) refers
to a heterogeneous group of anatomical anomalies
causing an obstruction in the urethra1. During fetal life,
LUTO entails a sequence of events that are detectable
on antenatal ultrasound examination. This typically
starts with evidence of a distended bladder (megacystis)
accompanied by hydronephrosis, progressing to renal
dysplasia with abnormal renal parenchymal appearance
on ultrasound examination and eventually resulting in
© 2017 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd ORIGINAL PAPER
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
2 Fontanella et al.
severe oligohydramnios2. The condition is associated with
a high rate of mortality and postnatal morbidity due
to lung hypoplasia and impaired renal function3. When
LUTO is suspected in the first trimester and megacystis
>12mm is seen, the prognosis is extremely poor and
parents often opt for termination of pregnancy4,5. For
cases identified later in pregnancy, no definitive criteria
for diagnosing LUTO and predicting the precise prognosis
have yet been proposed6. Beyond the first trimester, the
diagnosis of LUTO is typically based on the evidence of
three ultrasound findings: megacystis, dilated posterior
urethra (known as the keyhole sign), and either unilateral
or bilateral hydronephrosis.
Over the past 20 years, fetal therapy has been
attempted based on the assumption that, by relieving the
intracavitary pressure caused by the obstruction, mortality
and renal damage could possibly be prevented. The
PLUTO trial investigated this assumption, demonstrating
a significant improvement in survival of fetuses treated
with vesicoamniotic shunt, but reporting a high rate of
morbidity among survivors, irrespective of the antenatal
management7. To date, whether and when in-utero
treatment should be offered remains a matter of debate,
and the eventual selection of candidates is still suboptimal,
owing to the high number of false-positive LUTO cases8.
In fact, a previous study reported that one-third of
all LUTO cases suspected prenatally are reclassified
postnatally, primarily to vesicoureteral reflux9. For this
reason, an improvement in the diagnostic accuracy of
ultrasound for LUTO is called for.
The aim of this study was to identify the optimal
combination of ultrasound parameters for the antenatal
diagnosis of LUTO from the second trimester, as an
alternative to the commonly used LUTO triad (megacystis,
keyhole sign and hydronephrosis).
METHODS
This was a retrospective national study carried out
at all eight fetal medicine units (FMUs) of university
hospitals in The Netherlands. Cases were collected
according to the start of registration in databases; this
was from 2000 to 2015 in three centers (Erasmus
Medical Center, Rotterdam; Academic Medical Center,
Amsterdam; University Medical Center, Maastricht),
from 2004 to 2015 in two centers (University Medical
Center Groningen and Radboud University Medical
Center, Nijmegen), and between 2007 and 2014 in the
remaining centers (Leiden University Medical Center,
Leiden; Utrecht University Medical Center, Utrecht;
VU University Medical Center, Amsterdam). These
FMUs act as expert referral centers for all anomalies
suspected at peripheral hospitals and external ultrasound
clinics in The Netherlands. We included only cases
referred for fetal megacystis diagnosed from 18weeks’
gestation onwards, and therefore either directly after
the routine second-trimester examination or after an
ultrasound examination performed later in pregnancy for
growth or other obstetric indications. Fetal megacystis
was defined as an enlarged bladder failing to empty
during an extended ultrasound examination lasting at
least 40min.
The following antenatal data were collected at referral:
gestational age, fetal sex, evidence of keyhole sign or fetal
ascites (caused by leakage or rupture of the distended
bladder), hydronephrosis, amniotic fluid volume, renal
cortical appearance, right and left ureteral diameters,
and anteroposterior, transverse and longitudinal bladder
diameters. Bladder volume was calculated using the
formula10: longitudinal diameter × transverse diameter ×
anteroposterior diameter × π/6. The sum of right and left
ureteral diameters was calculated for each case, and for
ureters non-visualized at the ultrasound examination the
sum was considered to be 0mm. Amniotic fluid volume
was considered reduced in cases of a single deepest pocket
of <2 cm. Ultrasound reports were reviewed in order
to retrieve data on amniotic fluid volume, renal pelvis
dilatation and renal parenchymal echogenicity. Only the
first detailed ultrasound report at referral was used for
analysis.
Outcome data included all available postnatal data on
surgeries and medical examinations for liveborn infants,
and postmortem examinations for perinatal deaths,
when available. The term LUTO referred to a group
of anatomical anomalies causing urethral obstruction1.
This group thus included cases with posterior urethral
valves (PUV), urethral stenosis, urethral atresia and also
cases with LUTO reported as the final diagnosis but
without further details concerning the type of obstruction
(non-specified LUTO).
Antenatal baseline characteristics were compared using
the chi-square test or Fisher’s exact test for categorical
variables and the Student’s t-test for continuous vari-
ables. Univariate analysis was performed to examine
the association between candidate predictors and final
diagnosis. A logistic model was developed, first con-
sidering eight variables, and then using the backward
stepwise strategy to exclude progressively the weakest
predictors. Model performances were assessed using the
Hosmer–Lemeshow test for goodness of fit, and the dis-
criminative performance of the models was evaluated
by the area under the receiver–operating characteris-
tics (ROC) curve (AUC) using the predicted and the
actual outcomes. The model was validated internally
with bootstrapping using R-project software 3.4.2 (https:
//www.r-project.org/; package rms).
A clinical score was developed based on the results of
the logistic model. Sensitivity, specificity, positive (PPV)
and negative (NPV) predictive values were calculated.
Data analyses were performed using the statistical
software package SPSS Statistics 23 (IBM Corp., Armonk,
NY, USA).
RESULTS
During the study period, in total, 312 pregnancies were
referred because of suspected fetal megacystis from
the 18th week onwards. The outcomes of the 312
© 2017 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2018.
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pregnancies were 71 terminations of pregnancies, 10 cases
of intrauterine fetal death, 38 neonatal deaths and 193
liveborn infants. Ninety-eight cases (31%) were excluded
from the study because of missing or incomplete data
preventing a final diagnosis (in 55 cases autopsy was
declined and 43 cases were lost to follow-up) and 68 cases
(22%) were excluded because of incomplete antenatal
data or measurements. Moreover, three megacystis cases
not suspected of being LUTO were excluded from further
analysis, all of which presented polyhydramnios and
macrosomia, and an overgrowth syndrome was confirmed
after birth (Figure 1).
Based on postnatal investigations or postmortem
examinations, a final diagnosis was achieved in 143 cases,
including 124 (87%) true LUTO cases (74 PUV, four
urethral atresia, six urethral stenosis and 40 non-specified
LUTO) and 19 (13%) cases reclassified postnatally as
non-obstructive megacystis (12 infants with vesicoureteral
reflux, four cases of primary mega-ureters, one fetus
with megacystis-microcolon-intestinal hypoperistalsis
syndrome, and two cases without any evidence of
urological anomaly and with normal voiding at birth).
Descriptive statistics, sensitivity, specificity and results
of the univariate analysis according to final diagnosis
are presented in Tables 1 and 2. Longitudinal bladder
diameter showed poorer accuracy on univariate analysis
compared with bladder volume, and was therefore
excluded from further analysis. A ROC curve of bladder
volume was used to identify the optimal cut-off for
prediction of LUTO (AUC=0.66; 95% CI, 0.6–0.8;
P = 0.03; optimal cut off, 35 cm3). In addition, 13 cases
showed urinary ascites at referral with a collapsed urinary
bladder, suggesting that the severely enlarged bladder had
ruptured, thus making bladder volume measurement no
longer reliable. Therefore, severe megacystis was defined
by a bladder volume> 35 cm3 or ascites at referral.
Multivariate logistic regression analysis was performed,
starting with the inclusion of the following antenatal
variables considered as theoretically relevant in the
literature for the prospective diagnosis of LUTO: renal
cortical appearance (normal or abnormal); amniotic fluid
volume (normal or reduced); gestational age at referral
Fetal megacystis
(n = 312)
Excluded (n = 169):
 Incomplete data for final diagnosis (n = 98)
 Incomplete data on prenatal US (n = 68)








Figure 1 Flowchart of study population of patients referred for fetal
megacystis. LUTO, lower urinary tract obstruction; US, ultrasound.
(< or ≥ 28weeks’ gestation); hydronephrosis, degree
of bladder distension (mild or severe); fetal sex (female
or male); evidence of keyhole sign (yes or no); and
ureteral diameter as a continuous variable. The stepwise
backward method resulted in the progressive elimination
of variables with poorer performance. These variables
were fetal hydronephrosis, renal cortical appearance and
keyhole sign.
The final model included five predictive variables:
severe megacystis (odds ratio (OR), 4.21 (95% CI,
0.98–18.21); P = 0.054; after bootstrapping: P = 0.052);
ureteral size (OR, 1.25 (95% CI, 1.02–1.54), P = 0.035;
after bootstrapping: P = 0.029); oligohydramnios (OR,
3.7 (95% CI, 0.71–19.25); P = 0.12; after boot-
strapping: P =0.10); male sex (OR, 4.09 (95% CI,
0.88–18.88); P = 0.071; after bootstrapping: P = 0.04);
and referral before the 28th week (OR, 3.72 (95% CI,
1.18–11.72); P = 0.025; after bootstrapping: P = 0.019).
The Hosmer–Lemeshow test for goodness of fit showed
a good fit of this model with P = 0.94, considering
that P-values closer to 1 indicate a better fit. The
Table 1 Antenatal ultrasound characteristics in 143 cases referred







(n = 124) P
Male fetal sex 14 (74) 115 (93) 0.01
Keyhole sign 5 (26) 59 (48) 0.08
Echogenic kidneys 4 (21) 67 (54) <0.01
Oligo- or
anhydramnios
2 (11) 55 (44) <0.01
Hydronephrosis 15 (79) 108 (87) 0.29
Referral <28weeks 8 (42) 82 (66) 0.04
Gestational age at
referral (weeks)
25 (19–36) 23 (18–36)
Bladder volume (cm3) 18 (0.7–58) 31 (0.3–390) <0.01
Bladder longitudinal
diameter (mm)
36± 13 45± 18 0.03
Ureteral size*(mm) 1.8± 3.5 5.3± 7.2 <0.01
Data are given as n (%), median (range) or mean± SD. *Sum of
right and left ureteral diameters. LUTO, lower urinary tract
obstruction.
Table 2 Univariate analysis, sensitivity and specificity of variables
for antenatal diagnosis of lower urinary tract obstruction in 143
fetuses referred from second trimester for megacystis





Male fetal sex 4.56 (1.3–15.6) 93 26
Keyhole sign 2.54 (0.8–7.5) 48 74
Echogenic kidneys 4.41 (1.4–14.0) 54 79
Oligo- or anhydramnios 6.78 (1.5–30.6) 44 90
Referral <28weeks 2.69 (1.0–7.2) 66 58
Hydronephrosis 1.92 (0.6–6.6) 88 21
Severe megacystis* 5.16 (1.4–18.6) 49 84
*Bladder volume> 35 cm3 or ascites. OR, odds ratio.
© 2017 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2018.
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Table 3 Proposed clinical score for antenatal diagnosis of lower
urinary tract obstruction (LUTO)
Variable Points
Severe megacystis* 4
Bilateral ureteral diameters 1.3/mm†
Oligo- or anhydramnios 4
Male fetal sex 4
Referral < 28weeks 4
Score of ≥ 9.5 indicates LUTO. *Bladder volume> 35 cm3 or
















Figure 2 Receiver–operating characteristics curves for antenatal
diagnosis of lower urinary tract obstruction (LUTO) in 143 fetuses
referred from second trimester for megacystis, based on LUTO
clinical score ( ; area under the curve (AUC), 0.84; 95% CI,
0.75–0.93; P <0.001) and based on classic LUTO triad ( ;
AUC, 0.63; 95% CI, 0.49–0.77; P =0.07).
optimism-corrected model performance after bootstrap-
ping was 82%, 2% smaller than for the original dataset.
A clinical score was formulated based on the results of
the logistic regression model (Table 3). Figure 2 shows the
accuracy of this proposed clinical score in discriminating
LUTO from non-obstructive megacystis, compared with
that of a theoretical model based only on the commonly
used LUTO triad (AUC, 0.84 (95% CI, 0.75–0.93;
P < 0.001) vs 0.63 (95%CI, 0.49–0.77; P = 0.07)). ROC
curve analysis identified 9.5 as the optimal cut-off point
for the clinical LUTO score in predicting the risk of LUTO.
At this cut-off, the risk of LUTOwas 96%, sensitivity was
78% (95% CI, 70–85%), specificity was 79% (95% CI,
54–94%), PPV was 96% (95% CI, 91–98%) and NPV
was 36% (95% CI, 27–46%).
DISCUSSION
In this study, we proposed a clinical score for calculating
the risk of congenital LUTO during pregnancy, based
on five antenatal variables all evaluated at the detailed
ultrasound examination at referral: bladder distension
(severe or moderate); bilateral ureteral dilatation (as a
continuous variable); amniotic fluid volume (normal, or
oligo- or anhydramnios); fetal sex; and gestational age at
referral (< or≥ 28th week). This score demonstrated good
discriminative value in distinguishing true LUTO from
non-obstructivemegacystis, whichwould not be amenable
to antenatal treatment, and a better performance than
that of the classic antenatal triad. The use of this new
combination of ultrasound parameters enables optimal
identification of LUTO cases at the time of referral,
allowing for appropriate counseling and management
options.
The role of fetal therapy for LUTO is still debated in
the literature and the opportunity to gain high-quality
evidence has been missed due to the premature conclusion
of the PLUTO trial. A retrospective multicenter study
was published recently with the aim of exploring the
effectiveness of fetal therapy in cases with severe LUTO,
defined as megacystis, increased bladder-wall thickness,
bilateral severe hydronephrosis and oligohydramnios.
Despite the strict criteria, 23% of treated fetuses were
wrongly suspected of having LUTO6. We think that both
disease severity and selection of candidates for in-utero
treatment are influential determinants of the effectiveness
of fetal therapy, and that an improvement in the diagnostic
accuracy of antenatal ultrasound is thus needed.
In this study, fetal hydronephrosis was observed in 88%
of LUTO cases and in 79% of non-obstructive megacystis
cases. A recent review reported hydronephrosis in only
40–50% of LUTO cases and questioned the strength
of this association11. The keyhole sign demonstrated
high specificity (74%) but poor sensitivity (48%) for
LUTO (Table 2). Other studies12–14 have reported
previously poor accuracy of this ultrasound sign for
the prospective diagnosis of LUTO, in particular PUV.
It has been hypothesized that a possible explanation
for its low reliability is that miscellaneous types of
bladder dysfunction, such as detrusor instability and
bladder-sphincter dyssynergia, can cause dilatation of
the bladder neck. The latter has in fact been diagnosed
on voiding cystourethrogram in 30% of male infants
with vesicoureteral reflux15. Dilatation of the bladder
neck on prenatal ultrasound examination could mimic a
dilated posterior urethra, with an ultrasound appearance
similar to a keyhole, without being a true dilatation of the
posterior urethra13,16. Therefore, although the keyhole
sign and hydronephrosis have thus far been considered
as key findings of LUTO, and of PUV in particular, they
have poor predictive performance for the exact postnatal
diagnosis.
Amniotic fluid volume was included in the final model,
although it demonstrated poor sensitivity on univariate
analysis. In fact, in our cohort, 69/124 (56%) of LUTO
cases showed normal amniotic fluid at referral. This is
consistent with previous studies that reported a rate of
39%13, although they did not set a specific gestational
age for evaluating this parameter. Oligohydramnios is
© 2017 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2018.
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typically considered as a characteristic finding of LUTO,
as cases with non-obstructive megacystis are unlikely
to develop such an anomaly. For this reason, reduced
amniotic fluid volume is often used as an eligibility
criterion for in-utero treatment. However, some fetal
medicine experts argue that oligohydramnios occurs when
renal parenchyma has already been severely damaged
and, for this reason, in-utero treatment should rather be
offered to candidates with normal or only moderately
reduced amniotic fluid volume. Our results confirm that
the amniotic fluid volume, evaluated at the first detailed
ultrasound examination, can be used in evaluating the
risk of LUTO. However, its absence should not rule out
antenatal suspicion of LUTO.
Another notable finding of this study was that the
severity of bladder distension is an independent predictor
of LUTO. Our results showed that the likelihood
of LUTO was four-fold higher (OR, 4.21; P =0.05)
in cases of severe megacystis, defined by bladder
volume> 35 cm3 or fetal ascites at referral. Megacystis
has always been considered a key feature of LUTO,
with a high predictive value13. However, an objective
threshold to define megacystis during the second and
third trimesters is still lacking. Previous studies10,17
have investigated fetal urine production according to
gestational age in healthy fetuses without reporting
fetal bladder dimensions. Miscellaneous criteria have
been used in the literature for defining megacystis in
the second and third trimesters, ranging from bladder
length> 99th percentile for gestational age in the absence
of a nomogram18, to the most commonly used definition
of fetal bladder failing to empty during a period of 45
min19–22. There has not yet been a prospective study
published that has elucidated normal bladder dimensions
during the second and third trimesters of pregnancy and
defined a threshold for pathological enlargement. This is,
therefore, urgently needed.
A strength of this study is that, at variance with
previous studies, the antenatal variables were combined
in a multivariate analysis and only values recorded at
referral were considered. In spite of the fact that this
approach reduced our cohort to 143 cases, this is thus
far the largest study in the literature on the antenatal
diagnosis of LUTO.
This study also has some limitations. First, not all
the antenatal variables were measured directly by the
sonographer and, in a proportion of cases, the first author
(F.F.) measured them retrospectively from stored pictures.
This alsomeant that serial bladdermeasurements were not
available in most cases. Second, the retrospective design
meant that, for renal parenchymal appearance, we had to
rely upon the subjective judgment detailed in ultrasound
reports, rather than on an objective measurement. This
limitation may have affected the accuracy of this variable.
Statistical bootstrapping showed that overfitting of
the model was small, suggesting that the model could
hold for the overall population suspected to have LUTO.
However, external validation is essential before endorsing
this statement and supporting its clinical applicability.
To conclude, in order to improve the diagnostic
accuracy of LUTO in the second and third trimesters,
the criteria that need to be evaluated are fetal bladder
enlargement, ureteral dilatation, gestational age at
referral, fetal sex and evidence of oligo- or anhydramnios.
Future studies validating externally these results are
needed in order to refine the antenatal identification
of LUTO, prevent unnecessary fetal interventions and
optimize prenatal management.
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